In Defense of Evidence-based Medicine for the Treatment of COVID-19 Acute Respiratory Distress Syndrome

Ann Am Thorac Soc. 2020 Jul;17(7):787-789. doi: 10.1513/AnnalsATS.202004-325IP.

Authors

Todd W Rice¹, David R Janz^{2

3}

Affiliations

¹ Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
² University Medical Center, New Orleans, Louisiana; and.
³ Section of Pulmonary and Critical Care Medicine, Louisiana State University School of Medicine, New Orleans, Louisiana.

No abstract available

MeSH terms

Betacoronavirus / isolation & purification
COVID-19
Coronavirus Infections* / epidemiology
Coronavirus Infections* / physiopathology
Coronavirus Infections* / therapy
Critical Care Outcomes
Critical Care* / ethics
Critical Care* / methods
Critical Care* / standards
Critical Illness / therapy
Critical Pathways* / ethics
Critical Pathways* / standards
Empirical Research
Evidence-Based Medicine* / methods
Evidence-Based Medicine* / organization & administration
Humans
Pandemics*
Pneumonia, Viral* / epidemiology
Pneumonia, Viral* / physiopathology
Pneumonia, Viral* / therapy
Respiration, Artificial / methods
Respiration, Artificial / standards
Respiratory Distress Syndrome* / etiology
Respiratory Distress Syndrome* / therapy
SARS-CoV-2
Standard of Care